Iris Sadeh - Clal Biotechnology Accountant

All Insiders . Israel . 
Stock . Clal Biotechnology Industries . Stakeholders . Insider . Iris Sadeh
CBI Stock   36.40  0.50  1.39%   

Insider

Iris Sadeh is Accountant of Clal Biotechnology Industries
Phone972 3 612 1616
Webhttps://www.cbi.co.il

Clal Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
Clal Biotechnology Industries has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology has a current ratio of 3.6, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Clal Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Clal Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Clal Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Clal to invest in growth at high rates of return. When we think about Clal Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Yehuda AssayagMenora Miv Hld
61
Amir ShelahMigdal Insurance
65
Itay WeinsteinXTL Biopharmaceuticals
52
Liat StraussClal Insurance Enterprises
45
Lior RavivMigdal Insurance
45
Joseph BaruchMigdal Insurance
53
Ari KalmanMenora Miv Hld
72
Shlomo ShalevXTL Biopharmaceuticals
61
Sammy BassatHarel Insurance Investments
76
Ronen KantorXTL Biopharmaceuticals
N/A
Stein SagiMigdal Insurance
47
Moni FellerThe Phoenix Holdings
N/A
Dan BarOnMenora Miv Hld
59
Israel FeldingerIsrael Opportunity
35
Nataly MishanZakaiHarel Insurance Investments
49
Alon ElirazHarel Insurance Investments
52
Stuart ShapiraThe Phoenix Holdings
N/A
Uri SchorHarel Insurance Investments
N/A
Hila ConfortiClal Insurance Enterprises
60
Hadar BreenWeissClal Insurance Enterprises
53
Advocate IrShaiMenora Miv Hld
64
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. Clal Biotechnology Industries (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 21 people.

Management Performance

Return On Equity-0.45
Return On Asset-0.12

Clal Biotechnology Leadership Team

Elected by the shareholders, the Clal Biotechnology's board of directors comprises two types of representatives: Clal Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clal. The board's role is to monitor Clal Biotechnology's management team and ensure that shareholders' interests are well served. Clal Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clal Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Assaf Segal, Acting Officer
Iris Sadeh, Accountant
Liat Nissan, Controller
Shiran Manor, Co Sec
Etty Kliger, VP MediWound
Arnon MD, Medical Director
Pr MD, VP MediWound

Clal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clal Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.45
Return On Asset-0.12
Profit Margin(1.14) %
Operating Margin(0.86) %
Current Valuation89.12 M
Shares Outstanding156.85 M
Shares Owned By Insiders64.58 %
Price To Earning(218.28) X
Price To Book0.68 X
Price To Sales2.79 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Clal Stock

Clal Biotechnology financial ratios help investors to determine whether Clal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clal with respect to the benefits of owning Clal Biotechnology security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY